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Introduction
Allogeneic stem cell transplantation (allo-SCT) remains a highly effective therapy for hematopoietic 
malignancies that are not curable by chemotherapy and/or radiotherapy. The potentially curative nature 
of  SCT is due to generation of  a graft-versus-leukemia response, which is mediated by the donor immune 
system. However, this alloreactive immune response (AIR) can also result in graft versus host disease 
(GvHD), which remains one of  the major causes of  morbidity and mortality associated with allo-SCT. 
T cells are central to the initiation and maintenance of  the AIR, and quantitative and qualitative aspects 
of  T cell reconstitution after SCT are strongly linked to clinical outcome (1–3). The initial AIR is medi-
ated by mature T cells transferred within the donor stem cell graft (4), and several studies support the 
concept that the AIR is generated in the first 2 weeks after transplantation, in line with other primary T 
cell responses (5–11). In particular, the administration of  cyclophosphamide (Cy) at days 3–4 after SCT 
is effective at reducing the incidence of  GvHD and is believed to act through selective depletion of  prolif-
erating alloreactive T cells at this very early stage (12–18). An improved understanding of  T cell biology 
during the early AIR in human subjects might allow potential therapeutic intervention to selectively guide 
T cell alloreactivity toward elimination of  host hemopoiesis while minimizing risk of  GvHD. However, 
one of  the challenges with the study of  AIR in patients following allo-SCT is that transfer of  T cells into 
lymphopenic patients leads to intense homeostatic proliferation, which complicates assessment of  the 
response to antigen-specific allorecognition (19–21).
To isolate the effects of  the AIR, we characterized and contrasted T cell phenotype and function at 
2 weeks after transplant in allograft and autograft patients. We demonstrate that T cells from patients 
following allograft are highly activated, incorporated into the long-term T cell repertoire, and are 
recruited into GvHD-affected tissue. Transcriptional analysis identifies several potential targets for 
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early immunomodulation of  the AIR. These data provide a comprehensive characterization of  the 
early human T cell AIR and open avenues of  investigation for its potential modulation.
Results
Small numbers of  T cells are detectable within peripheral blood at 2 weeks after allograft and demonstrate relative 
expansion of  donor CD4 and CD8 effector cells. Blood samples were taken from 51 allograft and 38 autograft 
patients (Supplemental Table 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.97219DS1) at 2 weeks after transplantation, and the number and phenotype of  T 
cells was determined. The mean T cell count was 1.0 × 104 cells/ml within allograft patients and 5.5 × 104 
cells/ml in autograft patients, approximately 100-fold less than is found within healthy adults (Figure 1A). 
To determine the T cell differentiation state, we analyzed CCR7 and CD45RA expression to identify naive, 
Figure 1. Circulating differentiated allograft and autograft T cells are detectable at week 2 after SCT. (A) Number of T cells/ml of whole blood at 
week 2 after allo-SCT (n = 50) and auto-SCT (n = 22) and, for comparison, that in healthy donors (HDs; n = 6). Error bars represent SEM. (B) Represen-
tative flow cytometric plots demonstrating the presence of CD4 and CD8 T cell populations in an allo-SCT patient and an auto-SCT patient at week 
2 after SCT, and in a HD for comparison, that can be further differentiated by their expression of CCR7 and CD45RA (CD4 and CD8). (C) Comparison 
of the relative proportions of the naive, central memory (CM), effector memory (EM), and effector memory RA–positive (EMRA) phenotypes in CD4 
and CD8 T cells at week 2 after allo-SCT (n = 41 CD4, n = 35 CD8) and auto-SCT (n = 37) and, for comparison, HDs (n = 5). Data were analyzed using a 
Kruskal-Wallis test with Dunn’s multiple comparisons tests, *P < 0.05, **P < 0.01, ***P < 0.001. Error bars represent SEM.
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central memory, effector, and “CD45RA-revertant” effector memory subsets (Figure 1, B and C). CD4 and 
CD8 effector cells in allograft patients were already increased at week 2 and made up 54% and 62% of  the 
repertoire, respectively (P < 0.05 compared with healthy donors [HDs]). As anticipated, the proportion of  
naive T cells was significantly decreased in both patient groups compared with HDs (P < 0.05 for autograft 
CD4 and CD8 cells; P < 0.01 for allograft CD4 cells; and P < 0.001 for allograft CD8 cells). In line with 
previous studies (14, 22–24), chimerism analysis of  7 patients demonstrated that 98%–100% of  allograft T 
cells detected at week 2 were of  donor origin (data not shown).
Alloreactive T cell clonal expansions are identifiable by week 2, persist into the subsequent T cell repertoire, and 
demonstrate selective recruitment into tissue affected by GvHD. Having identified circulating T cell populations in 
the early period after transplant, we went on to examine whether cells present within allograft patients at 
this stage were implicated in the subsequent development of  clinical complications of  the AIR. T cell recep-
tor (TCR) Vβ family expression was assessed using FACS on T cells from paired stem cell product (SCP) 
and patient samples at week 2 after allograft or autograft transplant. Week 2 T cells from autograft patients 
retained a polyclonal repertoire. In contrast, the diversity of  TCR Vβ family expression after allograft con-
tracted markedly during this period, suggesting expansion of  specific T cells clones driven by antigen-specific 
allorecognition (Figure 2A). Importantly, this pattern was much more pronounced in patients who subse-
quently went on to develop acute GvHD (aGvHD), an important clinical complication of  AIR (P < 0.01; 
Figure 2A, top left).
aGvHD occurred at a median time point of  29 days after transplantation in our cohort, and, as such, 
we went on to determine the relative persistence of  week 2 T cell clones beyond this time point. TCRVB 
CDR3 sequencing was performed in 4 patients to track individual T cell clones from week 2 through to 2 
months and 5 months after transplant. Interestingly, clones that were present at week 2 after transplant were 
detectable at 2 months and 5 months in all 4 donors, demonstrating that T cell clones that emerge early 
after transplant contribute to the repertoire after transplant in the longer term (Figure 2B).
Based on these data, we were interested to see if  T cell clones present at week 2 would show prefer-
ential targeting to sites of  clinical aGvHD. Therefore, we compared TCRVβ CDR3 clonotypes present 
at week 2 with those identified from the liver biopsy of  a patient who developed acute liver GvHD at 96 
days after SCT (Figure 2C, left) and the skin biopsy of  a patient who developed acute skin GvHD (Sup-
plemental Figure 2). 94 T cell clones were shared between the week 2 blood and liver aGvHD samples 
(Figure 2C), with the most frequent of  these constituting 0.5% of  the liver repertoire (Figure 2C, right), 
increased by 100-fold from a frequency of  0.005% in week 2 blood. Together, these findings indicate that 
antigen-driven clonal T cells are present by week 2 following allograft and that these may be involved in 
the development of  aGvHD.
Week 2 allograft T cells are recently activated and undergoing intense proliferation with spontaneous production of  
cytokines. Our TCR sequencing data showed that week 2 T cell clones could persist and may play a role in 
the allogeneic response beyond the early time period after transplant. To examine whether these cells were 
functionally capable of  involvement in the AIR, we analyzed their phenotype and function and compared 
these findings to week 2 autograft T cells and cells from HDs. An analysis of  Ki67 expression demonstrated 
that >80% of  allograft T cells were proliferating. While a high degree of  proliferation is to be expected in 
such a lymphopenic environment, lymphocyte count–matched autograft patients had a significantly lower 
Ki67 expression (Figure 3A, P < 0.0001), indicating that the allograft proliferation may not be entirely 
attributable to the profound lymphopenia. In keeping with this, CD25 and CD69 expression showed a 
gradual decrease, starting with allograft T cells (where they were expressed by up to 98% of  the population 
in the “naive” [CCR7+CD45RA+] subset) through intermediate levels of  expression on autograft T cells 
to low levels on HDs (Figure 3B). The exception to this was for CD25 expression in the effector memory 
(CCR7–CD45RA–) subset, where autograft T cells had significantly greater levels of  expression (Figure 3B, 
P < 0.05) compared with both allograft and HD samples.
Next, we analyzed allograft and autograft T cells for production of  the cytokines IFN-γ and TNF-α 
and for CD107a expression. Strikingly, both CD4 and CD8 allograft week 2 T cells demonstrated con-
stitutive (i.e., without mitogenic stimulation) production of  these cytokines (Figure 3C). Quantitative 
analysis showed significantly higher levels of  IFN-γ, TNF-α, and CD107a in CD4 T cells from allograft 
patients compared with HDs (Figure 3D) and IFN-γ in CD8 T cells (Figure 3E). Allograft T cells also 
produced more cytokine that those from autografts, again suggesting that the allogeneic environment 
produced a T cell activation profile beyond that simply due to the lymphopenia and inflammatory 
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Figure 2. Week 2 T cell clones are implicated in the AIR, persist throughout the period immediately after transplant, and are detectable in 
GvHD-affected tissues. (A) An example of TCRVβ usage by T cells within the stem cell product (SCP; [top left]) and at week 2 (bottom left) after SCT 
from an allograft patient. Individual TCRVβ families are shown on the x axis; the y axis shows the percentage of total T cells expressing each individ-
ual TCRVβ family. The ratio of SCP and week 2 TCRVβ usage in patients who received autografts, received allografts and did not develop GvHD, and 
received allografts and did go on to develop GvHD is also shown. The number of TCRVβ families detected at week 2 is represented as a percentage of 
the number detected within the SCP in paired samples from individual patients. Data were analyzed by 2-tailed, Mann-Whitney U test, comparing No 
GvHD with GvHD and No GvHD with Auto, **P < 0.01. (B) Donut charts showing the percentage of the total T cell repertoire at 2 months after and 4–5 
months after allo-SCT in 4 patients (left to right) that is attributable to clones identified at week 2 (shown as percentages in the centre of the donuts). 
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environment associated with the SCT process. Polyfunctional capacity was seen in both allograft CD4 
and CD8 lineages, although it was more striking within the CD8 subset (Figure 3, D and E).
Week 2 allograft T cells display a transcriptional profile of  cellular activation and proliferation. Based on the data 
we had collected, we hypothesized that by 2 weeks after both autograft and allograft there was a change in 
T cell phenotype relative to HDs attributable to lymphopenia and the SCT process (Figure 4A). In allograft 
T cells alone, we hypothesized that there were changes in T cell phenotype (beyond the lymphopenia and 
SCT-associated changes) attributable to the allogeneic immune response (Figure 4A). To test this, T cells 
were sorted from autograft and allograft patients (matched for lymphocyte count to control for the influence 
of  homeostatic proliferation) at week 2 and subjected to RNA-sequencing (RNA-Seq) analysis (Figure 4A). 
This revealed a range of  genes that were upregulated in CD4 and CD8 T cells from allograft or autograft 
patients (Figure 4B; all differentially expressed genes are shown in Supplemental Data 1). Furthermore, 
gene set enrichment analysis (GSEA), performed using the MSigDB “hallmark” gene set (25), showed that 
gene sets selectively upregulated in allograft T cells were associated with increased levels of  activation and 
included gene ontology (GO) terms associated with cellular proliferation and the IFN-γ and α responses 
(Figure 4C; all significantly differentially expressed hallmark GO terms are shown in Supplemental Data 
1). Importantly, this profile, which reflected the cellular phenotype that we had observed at week 2, was not 
seen when the transcriptome of  SCP T cells taken from the same allograft and autograft patients was com-
pared. This indicates that the allograft-specific transcriptional signature is established in the period after 
SCT (all differentially expressed genes in allo-SCT and auto-SCT SCP are shown in Supplemental Data 1).
Several immune genes are selectively expressed in week 2 allograft T cells and represent potential candidates for 
early therapeutic immunomodulation. To further interrogate differences in the transcriptional immune pro-
file between allograft and autograft T cells, we performed GSEA, utilizing the “C7 immunologic signa-
tures” gene set, which is a compendium of  gene sets from >5,000 immune studies (26). In concordance 
with the hallmark GSEA analysis, the top 25 upregulated gene sets in allograft CD4 and CD8 week 2 
T cells were again all associated with leukocyte activation (represented in Figure 4D; Supplemental 
Figure 1B lists the top 25 terms from CD4 cells and the top 25 from CD8 cells, resulting in 37 unique 
terms; changes in all c7 gene sets are listed in Supplemental Data 1). C7 gene sets that were changed 
in the allografts compared with the autografts included those associated with antigenic stimulation (2 
data sets with GEO accession GSE36476; Supplemental Figure 1B) and those associated with an effec-
tor versus memory phenotype (2 GOLDRATH sets; http://software.broadinstitute.org/gsea/msigdb/
geneset_page.jsp?geneSetName=GOLDRATH_HOMEOSTATIC_PROLIFERATION; Supplemental 
Figure 1B). Finally, we utilized this information to identify proteins that might represent potential thera-
peutic targets for immune modulation of  the AIR in the early period after transplant. Specifically, genes 
were filtered to identify those with a ≥2 log2 increase in allografts but not autografts combined with 
annotation of  immunological function in the NIH immunology database and analysis portal (ImmPort) 
(27). This identified 8 genes within CD4 T cells that are selectively upregulated after allograft, including 
OX40L (TNFSF4) and TWEAK (TNFSF12) (Figure 4E). CD70 (TNFSF7) and FCER1G were identified 
as upregulated in CD8 allograft T cells (Figure 4E).
Discussion
Several studies have demonstrated that the AIR is established in the very early period following hemopoi-
etic transplantation. In particular, immunological parameters, such as T cell count and CD4/Treg ratio 
at week 2, carry prognostic importance (6–11), and early administration of  Cy reduces the incidence of  
GvHD (12, 13). A few studies have examined T cells during this early period after SCT in some detail (17, 
18, 28); although, notably, much of  the work has been performed after use of  the Cy protocol that depletes 
alloreactive T cells. Therefore, very little is known regarding the phenotype or function of  alloreactive T 
cells at this crucial stage of  immune activation.
Dark green shading represents clones not detectable at week 2. (C) H&E-stained section (original magnification, ×60) of liver from a liver aGvHD 
patient, showing infiltration of bile duct epithelium by atypical lymphocytes, associated with epithelial cell degenerative changes, indicative of aGvHD 
(top image). A section of liver with CD3 immunostaining from the same patient at (original magnification, ×20), showing infiltration of portal tracts, 
including bile ducts by CD3-positive lymphocytes (bottom image). Venn diagram showing the number of shared TCRβ chain CDR3 sequences (overlap 
between blue and pink sets) between week 2 (blue set) and GvHD-affected liver (pink set) in the same patient. Line graph showing the log10 frequency 
of reads for each T cell clone present in the blood at week 2 and in the liver at the point of aGvHD in the same patient.
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In the first part of  our work, we generated functional evidence for the role of  week 2 T cells in the 
AIR. Specifically, our data indicate that the T cell AIR is detectable at this time point, before development 
of  many of  its clinical symptoms. TCR Vβ family analysis demonstrated that autograft T cells retained a 
polyclonal T cell repertoire during the first 2 weeks of  expansion, whereas allograft cells developed an oli-
goclonal profile by this stage. Importantly, no differences were observed in the rate or severity of  infectious 
complications between auto- and allo-HSCT patients, suggesting that a differential response to infectious 
agents is not a significant explanation for these differences (Supplemental Figure 4). Moreover, this clonal 
restriction was much more profound in patients that subsequently developed aGvHD, suggesting that the 
repertoire changes associated with the AIR were detectable by week 2. This finding is corroborated by 
other studies demonstrating oligoclonality due to antigen-specific expansions (29) in the absence of  thymic 
export (30) and with reports that identify specific Vβ families as being associated with GvHD (31, 32). The 
relative oligoclonality in comparison with week 2 autograft T cells lends further weight to this argument. 
Clearly, a potential limitation of  the study is the difference in the conditioning and treatment protocols that 
are employed for patients undergoing autograft or allograft procedures, including the use of  alemtuzumab 
within allograft patients, which depletes both T cells and additional immune subsets. Lymphocyte count–
matched autograft and allograft samples were used to mitigate against these differences, as far as possible, 
and candidate target gene analysis focused specifically on immune genes.
Previous studies have indicated that T cell populations that become highly activated after SCT may 
fail to enter the memory pool due to intense and persistent activation by antigen on nonhematopoietic 
cells (29). As such, it was important to assess if  clones present at week 2 were recruited into the lon-
ger-term T cell repertoire: our data suggest that a substantial proportion of  the long-term repertoire is 
already established at week 2. In addition, we could show that T cell clones identified at week 2 were 
present 14 weeks later within liver aGvHD samples, with some clones showing up to 100-fold selective 
recruitment into tissue. Importantly, the functional capacity of  T cells at day 14 to recognize host tissue 
was measured by ELISPOT analysis, and alloreactive T cells were indeed detectable at week 2 after 
transplant (Supplemental Figure 3).
Our functional assays identified high levels of  proliferation, constitutive production of  inflammatory 
cytokines and upregulation of  markers of  activation by week 2 T cells from allograft patients. Our findings 
show that T cells are undergoing intense proliferation in the early after SCT period, with Ki67 expression 
observed on nearly all peripheral T cells. It is known that homeostatic proliferation is a potent stimulus for 
T cells (20, 21), but it is noteworthy that Ki67 expression was much lower in autograft recipients at this 
time point. As such, these data suggest that antigen-specific allorecognition is already well established at 
week 2. This proliferative phenotype was mirrored by the high level of  expression of  the activation markers 
CD69 and CD25 on both CD4 and CD8 allograft T cells. This was particularly striking on cells with a 
phenotypically “naive” phenotype, where both CD69 and CD25 were expressed by most of  the population 
(Supplemental Figure 5). Naive donor T cells, which are activated by recognition of  host peptide, play an 
important role in generation of  the AIR (30, 31), and these findings would suggest that this CD45RA+C-
CR7+CD69+CD25+ population represents cells that have undergone recent alloreactive recognition. A clin-
ical trial of  naive T cell depletion has indicated that the naive population is not entirely responsible for 
development of  the acute AIR (33). We also observed that CD69 and CD25 were upregulated on memory 
and effector T cells at day 14 after transplant, although it is not possible to determine if  this represents 
recently activated naive T cells or memory subsets. Previous studies have demonstrated that, while donor 
Figure 3. Week 2 T cells from allograft patients have a highly proliferative and activated phenotype. (A) Mean Ki-67 expression by T cells at week 
2 after allo-SCT (n = 13) and auto-SCT (n = 10) and, for comparison, healthy donors (HDs; n = 9). Error bars represent the SEM; data were analyzed 
by a 1-way ANOVA with a Tukey’s multiple comparisons test, ****P < 0.0001. (B) Expression of CD25 and CD69 by T cells at week 2 after allo-SCT 
(n = 7) and week 2 after auto-SCT (n = 5) and that in healthy donors (HDs; n = 5) on naive, CM, EM, and EMRA subsets. Data were analyzed using a 
Kruskal-Wallis test with a Dunn’s multiple comparisons test, *P < 0.05, **P < 0.01. (C) Representative FACS plots showing constitutive (i.e., without 
mitogenic stimulation) IFN-γ and TNF-α production (dot plots) and CD107a expression (histograms) by CD4 and CD8 week 2 T cells from an allograft 
patient (Allo). Representative plots from an autograft patient (Auto) are shown for comparison. (D) Expression of IFN-γ, TNF-α, and CD107a by CD4 
week 2 T cells from allograft patients (n = 9), autograft patients (n = 5), and HDs (n = 4). Data were analyzed by a Kruskal-Wallis test with a Dunn’s 
multiple comparisons test, *P < 0.05, **P < 0.01. Polyfunctionality plots showing number of functions exhibited by CD4 T cells from each allograft, 
autograft, and healthy donor. Each pie chart represents 1 individual. (E) Expression of IFN-γ, TNF-α, and CD107a by CD8 week 2 T cells from allograft 
patients (n = 9), autograft patients (n = 5), and HDs (n = 4). Data were analyzed by a Kruskal-Wallis test with a Dunn’s multiple comparisons test, *P 
< 0.05; **P < 0.01. Polyfunctionality plots showing number of functions exhibited by CD8 T cells from each allograft, autograft, and healthy donor. 
Each pie chart represents 1 individual.
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Figure 4. Week 2 allograft T cells have an activated phenotype at the transcriptional level. RNA-Seq was performed on CD4 and CD8 T cells isolat-
ed from both the stem cell product (SCP) and peripheral blood at week 2 from 4 allograft and 4 autograft patients. Autograft and allograft samples 
taken at week 2 were matched for lymphocyte count between patients to control for the influence of homeostatic proliferation due to lymphopenia. 
(A) Representation of experimental design. T cells transferred into an autograft patient will expand under the influence of homeostatic prolifera-
tion, whereas donor T cells that are transferred into an allograft patient will proliferate due to the combined influence of homeostatic proliferation 
and the allogeneic immune response (AIR). The transcriptome of week 2 T cells from both autograft and allograft patients were compared to iden-
tify the transcriptional changes associated with the AIR. (B) Volcano plots showing differential expression of genes in CD4 and CD8 T cells at week 
2 after transplant compared between allograft and autograft patients. Genes more highly expressed in autografts (FDR-adjusted P < 0.05) are high-
lighted in blue, and those more highly expressed in allografts (FDR-adjusted P < 0.05) are highlighted in red. (C) Heatmap showing all significant 
(false discovery rate–adjusted [FDR-adjusted] P < 0.05) hierarchically clustered GSEA q values for the MSigDB “hallmark” gene set. Values shown 
in blue are higher in autografts than in allografts, and values shown in red are those higher in allografts than in autografts. Columns represent gene 
sets, and rows represent pairwise comparisons. The first two rows represent FDR-adjusted P values for CD4 T cells, and the last 2 rows represent 
FDR-adjusted P values for CD8 T cells. (D) Heatmap showing the top 25 significant (FDR-adjusted P < 0.05) hierarchically clustered GSEA q values 
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memory and effector T cells play a variable and potentially less important role compared with naive T cells 
in the induction of  aGvHD (32, 34–36), these cells may be involved in the graft-versus-leukemia response, 
which is also part of  the AIR (36–39). CD69 expression was much lower on T cells following autograft, 
suggesting that this protein could be a useful marker of  cells that have undergone antigen-specific allorecog-
nition. Indeed, CD69 has been used for therapeutic pretransplant depletion of  alloreactive T cells following 
culture with host cells in vitro (40), and our findings indicate that this could also be of  value at week 2.
A particularly striking feature of  our ex vivo analyses was the finding that many T cells from allograft 
patients display spontaneous production of  cytokines without the need for stimulation with mitogens. This 
is a highly unusual feature, although it has been reported previously in leukemia cells and T cells infected 
with human T cell lymphotropic virus (41–44). Again, this phenotype was seen in only a small minority of  
T cells from autograft patients, which indicates that the alloreactive stimulation that occurs following allo-
geneic transplantation is a key requirement. Cytokine secretion could play a significant role in the develop-
ment of  GvHD, and this observation may indicate that anti-cytokine therapy could be of  clinical utility at 
this early stage. Collectively, these findings provide strong evidence that the T cell alloimmune response is 
detectable in the early period after transplant, well before the development of  associated clinical symptoms.
This characterization of  the developing AIR raises the possibility of  potential early therapeutic inter-
vention to manipulate the clinical outcome of  the transplant. As such, we examined the transcriptome 
of  week 2 CD4 and CD8 allograft T cells using RNA sequencing. An important control was that this 
information was compared with similar analysis of  samples from autograft patients with matched lym-
phocyte counts, enabling us to control for the effects of  homeostatic proliferation on T cell phenotype. 
GSEA analysis using “hallmark” and “immune” gene sets demonstrated that week 2 allograft T cells 
had high level expression of  genes associated with the cell cycle and T cell activation, revealing processes 
that are triggered by allorecognition rather than homeostatic expansion, in line with murine models (20). 
Interestingly, this pattern was similar across CD4 and CD8 cells, indicating involvement of  both major 
lineages in the alloreactive response. Transcriptional analysis was also used to identify genes that might 
represent potential therapeutic targets for modulation of  the AIR. Several immune genes were upregu-
lated in CD4 T cells, including two members of  the TNF superfamily, TNFSF4 and TNFSF12. TNFSF4 
encodes OX40L, whose primary expression is inducible on antigen-presenting cells, but which has also 
been demonstrated as a potent stimulatory ligand on subpopulations of  activated T cells and may serve 
to mediate autocrine regulation through OX40/OX40L ligation (45). TNFSF12 encodes the TWEAK 
cytokine ligand, an inducer of  apoptosis whose excessive expression has been associated with chronic 
inflammation and fibrosis (46). These findings implicate CD4 T cells as major effector cells in the immu-
nopathology associated with AIR and are supported by our finding of  high levels inflammatory cytokine 
production by CD4 cells in the early period after SCT. Additional upregulated genes encoded for a range 
of  proteins, including the secernin protein, SCRN1; perforin-like protein, MPEG1 (47); PARD3; the 
CD3-associated enzyme, CD3EAP; the tyrosine kinase, FGR; and the GTPAse, Rnd1. Two potential 
target genes were upregulated within the CD8 subset: the TNF family member CD70 and FCER1G. 
CD70 is expressed on highly activated T cells, and engagement with its ligand CD27 induces T cell pro-
liferation and cytotoxicity (48) and is believed to play a critical role in the initiation of  primary CD8 T 
cell responses (49). Genetic polymorphism within CD70 has been identified as a risk factor for GvHD, 
and murine models have demonstrated that CD70 blockade prevents rejection of  cardiac allografts (50). 
CD70 blockade in the early period after transplant may therefore represent an opportunity to suppress 
GvHD, and this potential is further supported by the identification of  CD70 as a direct therapeutic tar-
get on tumors (51). FCER1G is a high-affinity receptor of  IgE, and its role on CD8 T cells is currently 
unclear. Clearly, a potential limitation of  the study is the differences in treatment that autograft and 
allograft patients receive. We have tried to mitigate against these differences as far as possible by using 
lymphocyte count–matched autograft and allograft samples and by using immune genes specifically for 
for the MSigDB c7 “immunologic signatures” gene sets for CD4 and CD8 T cells, resulting in a total of 37 unique terms. Values shown in blue are 
those higher in autografts than in allografts, and values shown in red are those higher in allografts than in autografts. Columns represent gene 
sets, and rows represent pairwise comparisons. The first two rows represent FDR-adjusted P values for CD4 T cells, and the last two rows represent 
FDR-adjusted P values for CD8 T cells. (E) Bar plots showing log2 fold change for selected candidate genes for modulation of the AIR in both CD4 
(top) and CD8 (left) T cells. Candidate genes were selected on the basis on at least a log2 fold change of 2 and an adjusted P value of less than 0.05 
in allografts but not autografts and inclusion in the ImmPort database as a gene with an immunological function.
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our candidate target gene analysis. In addition, importantly, the differences in the allograft and autograft 
week 2 T cell transcription profiles were not reflected in the transcriptome of  the SCP T cells from the 
same autograft and allograft patients.
AIRs are critical determinants of  clinical outcome following human transplantation. These studies use 
the approach of  comparing autograft and allograft week 2 T cells to isolate and specifically characterize the 
early T cell AIR, demonstrating that this response is established very early after exposure of  the immune 
Figure 5. Week 2 allograft T cells have a unique phenotype. Schematic based on the data generated in this study. It shows the effect of homeostatic 
proliferation (represented in blue) followed by the alloreactive immune response (represented in red) on repertoire, proliferation, expression of activation 
markers, spontaneous production of cytotoxic cytokine, and the AIR-specific transcriptome of T cells after allo-SCT.
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system to allogeneic tissue. Our data describe a phenotype associated with week 2 alloreactive T cells, high 
levels of  proliferation, expression of  early activation markers, and spontaneous cytotoxic cytokine pro-
duction (summarized in Figure 5), reflected in the transcriptome of  the whole T cell population. Further 
detailed analysis of  the early alloreactive T cell population using this methodology has the potential to 
uncover a range of  novel therapeutic targets.
Methods
Patient cohort
Patients undergoing allogeneic or autograft SCT for hematological malignancies at the Queen Elizabeth 
Hospital Birmingham were enrolled on the study following full written informed consent (05/Q2707/175). 
All patient details are shown in Supplemental Table 1.
For GvHD prophylaxis, patients received either cyclosporine only or a combination of  cyclosporine 
and methotrexate. Patients were monitored clinically for 120 days after SCT and grouped according to 
the development of  clinically confirmed aGvHD during this period. Classification of  aGvHD was car-
ried out according to the NIH consensus criteria, which classifies patients with either classical aGvHD 
or delayed aGvHD (where typical features of  aGvHD present beyond 100 days after transplant, often 
in the context of  withdrawal of  immune suppression) (52). Patients who exhibited grade II–IV classical 
aGvHD were classified into the GvHD-positive group. Treatments received by each individual patient 
are indicated in Supplemental Table 1.
Sample collection
Peripheral blood. 10–50 ml peripheral blood was collected at week 1 and week 2 after transplant. Blood was 
taken into sodium heparin tubes for flow cytometric analysis or into EDTA tubes for Vβ TCR repertoire 
assessment or for chimerism analysis. For all subsequent experiments, fresh blood-derived T cells were used.
SCP. Following receipt of  the stem cell graft by patients, residual graft T cells from both allograft and 
autograft patients were retrieved from the stem cell bag by flushing with PBS. Stem cells were frozen in FCS 
containing 10% DMSO and stored at –80°C for later use.
Phenotypic analysis of T cells
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. Mononucle-
ar cells were surface stained with the appropriate, pretitrated antibodies (see below) on ice for 20 minutes, 
protected from light, and compared with unstained and fluorescence minus one controls.
T cell subsets were identified using the following monoclonal antibodies: αβTCR-Pacific blue (Bio-
legend, clone IP26), CD4-APC/Cy7 (BD Biosciences, clone RPA-T4), and CD8-V500 (BD Biosciences, 
clone RPA-T8) or CD8 PerCPVio700 (Miltenyi Biotech). Naive and memory populations were defined 
with CD45RA-AF700 (Biolegend, clone HI100) and CCR7 (APC or FITC) (R&D Systems, clone 150503) 
expression. CD25-PE/Cy7 (BD Biosciences, clone M-A251) and CD69-FITC (BD Biosciences, clone 
FN50) were included for analysis of  activation-associated molecule expression. Propidium iodide (PI) was 
added immediately prior to acquisition to exclude dead cells. Data were acquired on an LSR-II flow cytom-
eter and analyzed using FACSDiva software (both BD Biosciences) or acquired on a Gallios followed by 
analysis using Kaluza software (both Beckman Coulter). The lymphocyte population was identified by 
forward scatter/side scatter dot plots, and live T cells were then identified from this population by gating on 
PI–αβTCR+ cells. Clinical counts (lymphocytes per ml whole blood) were provided by the Queen Elizabeth 
Hospital for each patient.
Chimerism analysis
PBMCs were isolated from whole blood taken into EDTA at day 6–8 and day 12–14 after allo-SCT. T cells 
expressing αβTCR were purified by magnetic separation by staining with αβTCR-PE (Biolegend, clone 
IP26) followed by incubation with an anti-PE bead and purification on an MS column (Miltenyi Biotech). 
Purified T cells (89%–93% purity) were analyzed by microsatellite analysis at the West Midlands Region-
al Genetics Laboratory, Birmingham Women’s NHS Foundation Trust, Birmingham, United Kingdom. 
DNA was extracted from T cells using the Qiagen EZ1 tissue kit according to the manufacturer’s instruc-
tions using a Qiagen BioRobot EZ1 or EZ1 Advanced. A panel of  16 polymorphic microsatellite markers 
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(D4S2366, D2S1338, D13S742, Penta D, D10S2325, D12S391, D18S51, D13S634, D18S535, D6S957, 
D21S11, D18S386, D13S305, D21S1437, FGA, and Penta E) was PCR amplified from donor samples and 
recipient samples before and after transplant. PCR amplification was performed using fluorescently labeled 
primers (ABI) in a single-reaction tube (95°C for 15 minutes, 94°C for 30 seconds, 58°C for 1 minute 30 
seconds, 72°C for 1 minute 30 seconds) for 25 cycles at 72°C for 10 minutes). Standard reaction conditions 
were amplified from the 25 ng template DNA; however, for αβTCR T cells the quantity of  template DNA 
used varied from 12–25 ng, depending on the starting DNA concentration. Following PCR amplification, 
products underwent capillary electrophoresis using an ABI 3130 Genetic Analyzer. Peak labeling was per-
formed using ABI GeneMapper software. Donor and pretransplant recipient traces were assessed, and 
informative allelic configurations were identified (53), followed by data export and chimerism analysis 
using an Excel spreadsheet developed in-house. The percentage of  donor DNA in a sample was calculated 
from the relative peak heights and peak areas for donor and recipient from a minimum of  two markers with 
an informative allelic configuration. In-house corrections for stutter and preferential amplification of  short-
er alleles were applied. Results were reported as the median value of  the markers assessed. Importantly, 
typical sensitivity is 1%–2%; therefore, when 100% donor chimerism is reported, this does not exclude up 
to 2% host DNA. Full donor chimerism is defined as ≥98% donor, although if  host alleles are evident this 
would always be reported as mixed chimerism.
Analysis of Vβ family usage by flow cytometry
Vβ family usage was assessed using a TCR Vβ Repertoire Kit (Beckman Coulter) in combination with CD3-
PC5 (Beckman Coulter, clone UCHT1). Cells were analyzed using an LSR-II flow cytometer (BD Biosciences)
DNA isolation and TCRB CDR3 analysis
Genomic DNA was isolated from MACS-sorted (Miltenyi Biotech) T cells (>95% purity) using the 
QIAamp DNA mini kit as per the manufacturer’s protocol. Sequencing of  the TRB locus was performed 
at Adaptive Biotechnologies using the immunoSEQ assay at survey-level resolution. Initial analysis of  
sequence reads was performed at Adaptive Biotechnologies using the ImmunoSEQ software tool (Adaptive 
Biotechnologies). The TCRB CDR3 region was defined as previously described (54). Sequences that did 
not match CDR3 sequences were removed from the analysis. Sequences that included insertions or dele-
tions resulting in frame shifts or contained premature stop codons were discarded from the analysis, as were 
sequences that did not resolve to a V, D, and J family.
Ex vivo analysis of cytokine production and CD107a expression
For analysis of  cytokine production and CD107a degranulation, PBMCs were resuspended in RPMI con-
taining 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mM L-glutamine, and 10% FCS and incubated 
with monensin (1.25 μg/ml and anti-CD107a FITC (BD Biosciences, clone H4A3) for 4 hours. Following 
incubation, cells were stained with the phenotyping antibodies listed above. They were then fixed (2% 
PFA), permeabilized (1% Saponin), and incubated with the monoclonal antibodies TNF-α-PE-Cy7 (Ebio-
science, clone MAb11) and IFN-γ-AF700 (Biolegend, clone 45.B3) for 20 minutes at room temperature. 
Cells were analyzed using an LSR-II flow cytometer (BD Biosciences).
RNA extraction, sequencing, and alignment
RNA was extracted from FACS-sorted T cells (>99% purity) from 4 allograft and 4 autograft patients (Sup-
plemental Figure 1A) using the Qiagen RNeasy micro kit, according to the provided protocol. Extracted 
RNA was then submitted to Oxford Gene Technologies for RNA-Seq on a HiSeq 2000/2500 as 100–base 
paired end reads. The preprocessing of  RNA-Seq data included trimming of  Fastq reads with Prinseq (55) 
followed by mapping of  the reads to the hg19 reference genome using Star Aligner (56). After successful 
alignment to the reference genome, the reads were quantitated using HTSeq (57). The RNA-Seq data are 
available in the GEO database (https://www.ncbi.nlm.nih.gov/geo/) under accession GSE111377.
Differential expression and GSEA
DESeq2 (version 1.14.1) (58) was used to perform differential expression analysis and to compute fold 
changes. T cells were compared between allograft and autograft SCP samples and across allograft and 
autograft week 2 samples. CD4 and CD8 T cell contrasts were performed independently, resulting in a total 
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of  4 pairwise comparisons. Genes were considered differentially expressed at an FDR-adjusted P value 
threshold of  less than 0.05.
For GSEA, genes with a log2 fold change of  0 were removed to avoid rank ties. Ensembl identifiers 
were converted to Entrez identifiers using biomaRt (version 2.30.0). GAGE (version 2.24.0) was used for 
all GSEA analyses and to retrieve GO annotations. For further analysis, the MSigDB (v5.2) hallmark (25) 
and c7 immunologic signatures (26) were used. For display in Figure 4C and Figure 5, the most significant 
differentially regulated pathways were hierarchically clustered based on the lower and greater FDR-adjust-
ed P values for each of  the 4 pairwise comparisons.
Candidate gene selection
Candidate genes were selected from the differentially expressed set of  genes (FDR-adjusted P < 0.05), 
with the additional criteria that each gene shows an absolute fold change of  above 2 and that each gene is 
listed in the ImmPort database (27) as having an immunological function. Candidate gene selection was 
performed independently for CD4 and CD8 T cells.
Statistics
Univariate analyses comparing two groups were performed using a Mann-Whitney U test. For analyses 
involving more than two groups, either a 1-way ANOVA with Tukey’s multiple comparison test or a Kru-
skal-Wallis with Dunn’s multiple comparisons test was used. Tests were performed using GraphPad Prism 
(version 7.02; GraphPad Software Inc.). For TCR CDR3 region analysis, all plots and statistical analyses 
were performed in R version 3.2.0.
Study approval
Patients undergoing allogeneic or autograft SCT at the Queen Elizabeth Hospital Birmingham were 
enrolled in the study following full written informed consent (05/Q2707/175). The ethics of  this study 
have been approved by the NHS National Research Ethics Service (NRES) Committee, West Midlands, 
South Birmingham, United Kingdom.
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